Mid Pharma Companies Show Strength In Dealmaking

Datamonitor Healthcare's mid pharma peer set, a group that boasts efficiency in R&D but still relies on business development for growth, has signed a significant number of alliances over the past six years to build out the pipeline in innovative areas.

IV1702_WordCloud_Mid Pharma_1200

The mid pharma peer set – defined by Datamonitor Healthcare (DMHC) as companies with less than $10 billion in annual revenue, excluding biotechs, generics companies, and Japanese pharmaceutical companies – brings just as much power to the dealmaking table as its big pharma counterpart. As a group, mid pharma companies boast efficiency in R&D that surpasses that of big pharma and other groups, thanks in part to a handful of very strong drug launches over the past several years that includes Gilead Sciences Inc.’s multi-billion-dollar hepatitis C franchise. (Also see "Pharma R&D Efficiency: Mid-Sized Companies Excel" - In Vivo, 29 August, 2016.) The mid pharma peer set still relies on business development for growth, with nearly all of the companies having evolved their biopharmaceutical businesses through acquisition. Over a nearly six-year timeframe from Q1 2011 through Q3 2016, mid pharma companies signed partnerships worth $10 billion in up-front licensing value, according to Informa's Medtrack and Strategic Transactions. (See Exhibit 1.) Among therapeutic categories, oncology held the top spot in alliance volume.

According to DMHC's new report Mid Pharma Licensing and M&A Trends, 2011-2016, mid pharma companies did a total...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.